Revolutionizing Medicine
Custom organoid screening models
Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.
- Tumor Origin: Pan-Cancer, client-selected indications
- Molecular Profiling: Client-selected molecular alterations, mutations, CNVs, fusions, etc.
Predefined organoid screening models
Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.
- PanTumor 60™: primary and metastatic tumors
- Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver
- Molecular Profiling: Tempus xT molecular profiles and whole transcriptome
- PanTumor IO™: primary and metastatic tumors with allogeneic MHC-matched PBMCs
- Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver
- Molecular Profiling: Tempus xT molecular profiles and whole transcriptome, four digit HLA genotyping
- Designed to screen cell engagers and adoptive cell therapeutics
Single cell RNA sequencing
Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response
Spatial transcriptomics
Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response